Free tool
FAERS Monitor: Sotalol Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022306 or its brand name (Sotalol Hydrochloride, Sotalol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,515
Serious
2,111
84% of reports
Hospitalization
1,122
Death reported
254
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- atrial fibrillation171
- electrocardiogram qt prolonged148
- drug ineffective143
- hypotension123
- dyspnoea117
- bradycardia111
- dizziness110
- drug interaction99
- nausea93
- fatigue92
- fall86
- acute kidney injury72
- ventricular tachycardia72
- off label use71
- asthenia63
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 31 |
| 2006 | 127 |
| 2007 | 234 |
| 2008 | 30 |
| 2009 | 123 |
| 2010 | 30 |
| 2011 | 79 |
| 2012 | 107 |
| 2013 | 57 |
| 2014 | 66 |
| 2015 | 54 |
| 2016 | 76 |
| 2017 | 95 |
| 2018 | 123 |
| 2019 | 146 |
| 2020 | 110 |
| 2021 | 94 |
| 2022 | 139 |
| 2023 | 149 |
| 2024 | 193 |
| 2025 | 253 |
| 2026 | 153 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,644 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ventricular tachycardiaSignal | 72 | 36.6 | 29.1 | 2,450 |
| electrocardiogram qt prolongedSignal | 148 | 34.6 | 29.5 | 4,777 |
| bradycardiaSignal | 111 | 17.5 | 14.6 | 1,716 |
| atrial fibrillationSignal | 171 | 14.7 | 12.7 | 2,177 |
| drug interactionSignal | 99 | 5.2 | 4.3 | 336 |
| hypotensionSignal | 123 | 5.1 | 4.3 | 409 |
| acute kidney injurySignal | 72 | 3.9 | 3.1 | 156 |
| fallSignal | 86 | 2.2 | 1.8 | 53 |
| dizziness | 110 | 1.8 | 1.5 | 43 |
| dyspnoea | 117 | 1.7 | 1.4 | 36 |
| asthenia | 63 | 1.4 | 1.1 | 7 |
| fatigue | 92 | 1.0 | 0.8 | 0 |
| nausea | 93 | 1.0 | 0.8 | 0 |
| drug ineffective | 143 | 0.9 | 0.8 | 1 |
| off label use | 71 | 0.7 | 0.5 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.